Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Bases de dados
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Molecules ; 28(23)2023 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-38067591

RESUMO

BACKGROUND: Neuropathic pain is drug-resistant to available analgesics and therefore novel treatment options for this debilitating clinical condition are urgently needed. Recently, two drug candidates, namely mirogabalin and cebranopadol have become a subject of interest because of their potential utility as analgesics for chronic pain treatment. However, they have not been investigated thoroughly in some types of neuropathic pain, both in humans and experimental animals. METHODS: This study used the von Frey test, the hot plate test and the two-plate thermal place preference test supported by image analysis and machine learning to assess the effect of intraperitoneal mirogabalin and subcutaneous cebranopadol on mechanical and thermal nociceptive threshold in mouse models of neuropathic pain induced by streptozotocin, paclitaxel and oxaliplatin. RESULTS: Mirogabalin and cebranopadol effectively attenuated tactile allodynia in models of neuropathic pain induced by streptozotocin and paclitaxel. Cebranopadol was more effective than mirogabalin in this respect. Both drugs also elevated the heat nociceptive threshold in mice. In the oxaliplatin model, cebranopadol and mirogabalin reduced cold-exacerbated pain. CONCLUSIONS: Since mirogabalin and cebranopadol are effective in animal models of neuropathic pain, they seem to be promising novel therapies for various types of neuropathic pain in patients, in particular those who are resistant to available analgesics.


Assuntos
Neuralgia , Nociceptividade , Camundongos , Humanos , Animais , Oxaliplatina/uso terapêutico , Estreptozocina , Analgésicos/farmacologia , Analgésicos/uso terapêutico , Neuralgia/tratamento farmacológico , Paclitaxel/farmacologia , Paclitaxel/uso terapêutico
2.
Molecules ; 26(3)2021 Jan 25.
Artigo em Inglês | MEDLINE | ID: mdl-33503911

RESUMO

BACKGROUND: Wide use of oxaliplatin as an antitumor drug is limited by severe neuropathy with pharmacoresistant cold hypersensitivity as the main symptom. Novel analgesics to attenuate cold hyperalgesia and new methods to detect drug candidates are needed. METHODS: We developed a method to study thermal preference of oxaliplatin-treated mice and assessed analgesic activity of intraperitoneal duloxetine and pregabalin used at 30 mg/kg. A prototype analgesiameter and a broad range of temperatures (0-45 °C) were used. Advanced methods of image analysis (deep learning and machine learning) enabled us to determine the effectiveness of analgesics. The loss or reversal of thermal preference of oxaliplatin-treated mice was a measure of analgesia. RESULTS: Duloxetine selectively attenuated cold-induced pain at temperatures between 0 and 10 °C. Pregabalin-treated mice showed preference towards a colder plate of the two used at temperatures between 0 and 45 °C. CONCLUSION: Unlike duloxetine, pregabalin was not selective for temperatures below thermal preferendum. It influenced pain sensation at a much wider range of temperatures applied. Therefore, for the attenuation of cold hypersensitivity duloxetine seems to be a better than pregabalin therapeutic option. We propose wide-range measurements of thermal preference as a novel method for the assessment of analgesic activity in mice.


Assuntos
Analgésicos/farmacologia , Hiperalgesia/tratamento farmacológico , Dor/tratamento farmacológico , Animais , Antineoplásicos/farmacologia , Temperatura Baixa , Modelos Animais de Doenças , Cloridrato de Duloxetina/farmacologia , Temperatura Alta , Masculino , Camundongos , Oxaliplatina/farmacologia , Medição da Dor/métodos , Pregabalina/farmacologia , Temperatura
3.
Neural Comput Appl ; 26(3): 723-734, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25798031

RESUMO

In this report, the parameters identification of a proportional-integral-derivative (PID) algorithm implemented in a programmable logic controller (PLC) using support vector regression (SVR) is presented. This report focuses on a black box model of the PID with additional functions and modifications provided by the manufacturers and without information on the exact structure. The process of feature selection and its impact on the training and testing abilities are emphasized. The method was tested on a real PLC (Siemens and General Electric) with the implemented PID. The results show that the SVR maps the function of the PID algorithms and the modifications introduced by the manufacturer of the PLC with high accuracy. With this approach, the simulation results can be directly used to tune the PID algorithms in the PLC. The method is sufficiently universal in that it can be applied to any PI or PID algorithm implemented in the PLC with additional functions and modifications that were previously considered to be trade secrets. This method can also be an alternative for engineers who need to tune the PID and do not have any such information on the structure and cannot use the default settings for the known structures.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA